User:Kkkkkk22/sandbox

Angene Biotechnology (Hong Kong) is a research phase biotechnology start-up founded in partnership with Sungkyun Biotech Co. Ltd. (Korea). Its mission is to optimize proprietary oncological therapeutic and diagnostic technologies to offer new peace of mind and hope for cancer patients.

History
Incorporated on October 29, 2018, Angene Biotechnology received grant funding from the Hong Kong Innovation and Technology Council’s Innovation and Technology Fund to develop the diagnostics technology in Hong Kong with a local university partner.

Pipeline
Angene Biotechnology (Hong Kong) 's flagship product is an over-the-counter cancer urinalysis test, currently being prepared for clinical trials at the Chinese University of Hong Kong's Phase 1 Clinical Trial Centre. The expected time to market is late 2022. It is a technology derived from a suite of antibodies that can be used to detect EN2 proteins, a cancer biomarker.